BRAF and central nervous system cancer: In an open-label, nonrandomized multicohort, ‘basket’ study (VE-BASKET) efficacy and safety of vemurafenib monotherapy was shown in patients with nonmelanoma tumor including 24 BRAF-V600E mutated gliomas [82].